The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.50
Bid: 36.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 3.00 (8.333%)
Open: 37.50
High: 37.50
Low: 37.50
Prev. Close: 37.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Beximco Pharma wins at Scrip Awards 2017

30 Nov 2017 10:30

RNS Number : 9866X
Beximco Pharmaceuticals Ltd
30 November 2017
 

30 November 2017

 

BEXIMCO PHARMACEUTICALS LTD.

 

Beximco Pharma wins Best Company in an Emerging Market at the 2017 Scrip Awards

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the Company has won the award for the 'Best Company in an Emerging Market' at the Scrip Awards, presented in London, England, on 29 November 2017. Rabbur Reza, Chief Operating Officer of Beximco Pharma, accepted the award on behalf of the Company.

 

In its 13th year, the Scrip Awards programme recognises the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. The awards provide the industry with an opportunity to acknowledge its highest achievers across all parts of the value chain and to recognise both corporate and individual achievement. A panel of 16 highly respected and independent judges from across diverse sectors evaluated the award entries to select the finalists.

 

Beximco Pharma Managing Director, Mr Nazmul Hassan MP, commented:

"I am honoured and excited that Beximco Pharma has been selected as the 'Best Company in an Emerging Market' at the prestigious Scrip Awards. As a Company that is currently exporting products to over 50 countries and producing more than 500 products encompassing broad therapeutic categories, Beximco Pharma is continuing to expand its reach and impact around the world. As the only Company in Bangladesh to export pharmaceutical products to the US, we are setting a high standard for the pharmaceutical industry in Bangladesh. I look forward to our continued advancement as we strengthen our research and development capabilities, create new partnerships and build our presence in both domestic and international markets."

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 58611891, +880 2 58612040, Ext 10140

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

 

Northland Capital Partners Limited (Broker)

Gerry Beaney / Tom Price

Tel: +44 (0)20 3861 6625

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,500 employees of the Company.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAWGGQPGUPMGUU
Date   Source Headline
27th Dec 20187:00 amRNSEGM Statement
30th Nov 20187:00 amRNSAGM Notification
30th Nov 20187:00 amRNSEGM Notification
29th Nov 20188:30 amRNSBeximco Pharma wins at Scrip Awards 2018
14th Nov 20187:00 amRNSResults for First Quarter Ended 30 September 2018
7th Nov 20187:00 amRNSResults for the 12 month period ended 30 June 2018
26th Oct 20187:00 amRNSNotification of Preliminary Results and AGM
30th Jul 20187:00 amRNSUS FDA Approves Beximco Pharma's Nadolol Tablets
23rd Jul 20187:00 amRNSCommences export of fourth product to the US
27th Apr 20187:00 amRNS3rd Quarter Results
23rd Apr 20187:00 amRNSCommences Export of Third Product to the US Market
3rd Apr 20187:00 amRNSCompletion of the Acquisition of Nuvista Pharma
30th Jan 20187:00 amRNSHalf Year Results 2017-18
19th Jan 20187:00 amRNSPayment of Cash Dividend
19th Jan 20187:00 amRNSAcquisition of a Majority Stake in Nuvista Pharma
27th Dec 20177:00 amRNSAGM Statement
30th Nov 201710:30 amRNSBeximco Pharma wins at Scrip Awards 2017
23rd Nov 201711:53 amRNSNotice of AGM
14th Nov 20177:00 amRNSResults for First Quarter Ended 30 September 2017
7th Nov 20177:00 amRNSCommencement of Second Product Export to the US
6th Nov 201710:30 amRNSResults for the 12 month period ended 30 June 2017
26th Oct 20177:00 amRNSNotice of Preliminary Results and AGM
6th Oct 20177:00 amRNSSigns a Non-Binding MoU with Nuvista Pharma
2nd Oct 20177:00 amRNSChange of Broker
18th Sep 20177:00 amRNSCommences Export to Canada
25th Jul 20177:00 amRNSFDA approves Beximco Pharma Methocarbamol tablets
28th Apr 20177:00 amRNSFinancial Results for the Third Quarter of 2016-17
27th Jan 20177:00 amRNSHalf year results 2016-17
25th Jan 20177:00 amRNSBeximco Pharma forms JV with BioCare Manufacturing
19th Dec 20167:00 amRNSUS FDA approves Metformin for diabetes control
16th Dec 201610:12 amRNSPayment of Cash Dividend
12th Dec 20161:54 pmRNSStock Dividend Issued and Total Voting Rights
21st Nov 20167:00 amRNSAGM Statement
15th Nov 20167:00 amRNS1st Quarter Results
25th Oct 20167:00 amRNSReceives second product approval from the US FDA
20th Oct 20167:00 amRNSResults for the 18 month period ended 30 June 2016
19th Oct 20167:00 amRNSNotice of AGM
7th Oct 20167:00 amRNSNotification of Preliminary Results and AGM
5th Aug 20167:00 amRNSBeximco Pharma commences export to the US
17th Jun 20167:00 amRNSBeximco Pharma commences export to Kuwait
9th May 20167:00 amRNSFinal Results
6th May 20167:01 amRNSAGM Change and Dividend Update
6th May 20167:00 amRNSChange of Accounting Reference Date
4th May 20167:00 amRNSAmendment to Notification of Preliminary Results
21st Apr 20167:00 amRNSNotification of Preliminary Results and AGM
19th Nov 20157:00 amRNSUS FDA approval to manufacture blood pressure drug
27th Oct 20157:00 amRNS3rd Quarter Results
24th Jul 20157:00 amRNSHalf Yearly Report
13th Jul 201510:53 amRNSPayment of Cash Dividend
26th Jun 20157:00 amRNSStock Dividend Issued and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.